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TranssulfurationBackground/aim: Plasma total homocysteine (tHcy) is elevated in patients with persistent vs. paroxysmal atrial
fibrillation (AF), and has been related to increased risk of new-onset AF. Homocysteine is degraded to cystathio-
nine (Cysta) and cysteine (Cys). All three metabolites have been linked to potential proarrhythmic traits such as
inflammation and atrial fibrosis. We evaluated the prospective association between these metabolites and new-
onset AF among patients with suspected stable angina pectoris.
Methods: Information regarding AF was obtained by linking patient data to national health registries. Risk asso-
ciations were explored by Cox regression and potential improvements in risk reclassification were calculated by
the continuous net reclassification index (NRI N 0).
Results: At baseline, 3535 patients without any prior history of AF were included. During median follow-up of
7.4 years, 392 patients (10.2%) were registered with incident AF. Higher plasma tHcy and tCys were associated
with increased risk of incident AF [age and gender adjusted HRs (95% CI) per 1 log transformed SD 1.23
(1.12–1.35) and 1.23 (1.11–1.38)];multivariate adjustment yielded similar results. Plasma tHcy and tCys also im-
proved reclassification of patients (NRI N 0 (95% CI)) for tHcy 0.118 (0.02–0.22) and tCys 0.107 (0.002–0.21). No
association was seen between plasma Cysta and incident AF.
Conclusion: Plasma tHcy and tCys, but not Cysta, were associated with, and improved risk classification of, new-
onset AF among patients with stable angina pectoris. Our results motivate further studies to explore the relation-
ship between homocysteine metabolism and cardiac arrhythmias.
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Atrial fibrillation (AF) is the most common clinically significant ar-
rhythmia, and the prevalence and incidence are increasing. AF is associ-
ated with increased mortality, morbidity and health care costs, and
important risk factors for AF include higher age, male gender,index; CBS, cystathionine beta-
sease; CVDNOR, cardiovascular
FR, estimated glomerular filtra-
d-diastolic pressure; LVEF, left
xal 5-phosphate; ROS, reactive
al plasma homocysteine; tCys,
in intervention trial.
spital, Pb 1400, 5021 Bergen,
gsson).
. This is an open access article underhypertension, smoking and diabetes. Biomarkers, however, have a
minor role in the assessment of AF risk [1]. It is therefore of great inter-
est to identify novel biomarkers that can contribute in AF risk prediction
of patients with cardiovascular disease (CVD), as well as in exploring
potential pathophysiological mechanisms.
Homocysteine (Hcy) is a non-essential amino acid. It is metabolized
via the transsulfuration pathway by the pyridoxal 5′-phosphate (PLP)
dependent enzymes cystathionine-beta-synthase (CBS) and
cystathionase to cystathionine (Cysta) and cysteine (Cys), respectively.
Hcy may also be remethylated to methionine [2].
Elevated plasma total homocysteine (tHcy) is associated with CVD
and predominantly atherosclerotic CVD [3], however any causal effects
are still elusive [4]. Pre-clinical studies suggest that Hcy affects electrical
activity in the human atria [5]. Higher plasma tHcy is associated with
prevalent AF [6], and notably a recent study link tHcy with incident AF
[7], as well as being an independent risk marker for early recurrencethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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[9], and total plasma cysteine (tCys) have been linked with CVD [10],
but have hitherto not been studied according to AF risk.
We therefore investigated the potential associations between
plasma tHcy, Cysta and tCys with incident AF in a large prospective Nor-
wegian cohort of patients evaluated for stable angina pectoris.
2. Material and methods
2.1. Study population
The study population has been described in detail elsewhere [11]. In
short, 4166 patients underwent coronary angiography at two Norwe-
gian university hospitals due to suspected stable angina pectoris in the
period 2000–2004. Approximately 2/3 of the patients were included
in the Western Norway B-Vitamin Intervention Trial (WENBIT), a ran-
domized controlled trial investigating B-vitamin treatment as second-
ary CVD prevention [12]. In the present study we excluded patients
without valid measurements of plasma tHcy, Cysta or tCys leaving
3856 patients for the final baseline analyses. For the prospective analy-
ses, we also excluded 321 patients with AF at baseline, leaving a total of
3535 patients for the current analyses.
All patients provided written informed consent and the study was
carried out according to the Declaration of Helsinki.
2.2. Baseline data
The collection of anamnestic, clinical and anthropometric data has
been described in detail elsewhere [11]. Self-reported anamnestic data
were provided by the patient, and checked against medical records
when available. Health care personnel assessed anthropometric data
specific to the study.
2.3. Laboratory analyses
Venous blood sampleswere drawn 1–2 days prior to or immediately
after angiography. The majority of patients were non-fasting (n =
2659). Routine laboratory analyseswere performed on fresh blood sam-
ples at each recruiting hospital, whereas study-specific analyses were
performed at the laboratory of Bevital AS (www.bevital.no) on samples
stored at−80 °C and later thawed before analyses by personnel blinded
to the study outcomes. Plasma tHcy, Cysta and tCys concentrationswere
determined by gas chromatography/tandem mass spectrometry [13].
2.4. Endpoint data
The endpoint of interest was receiving a diagnosis of AF (according
to the International Classification of Diseases 10th edition I48) during
hospitalization or death due to AF throughout 31 December 2009. End-
point data regarding receiving a diagnosis of AF during hospitalization
were retrieved from the Cardiovascular Disease in Norway project
(CVDNOR; https://cvdnor.b.uib.no), which provides data on CVD diag-
noses at discharge from Norwegian hospitals in the period 1994–2009
[14]. Data regardingdeath due to AFwere retrieved from theNorwegian
Cause of Death Registry (https://www.fhi.no/en/hn/health-registries/
cause-of-death-registry/cause-of-death-registry-/). Endpoint data
were linked to each patient using the 11 digit personal identification
number, unique to each Norwegian resident.
2.5. Statistical analyses
Continuous and categorical data are presented as median (25–75
percentiles) and counts (%), respectively, and differences according to
new-onset AF were tested by Mann-Whitney-U and Chi square test.
We calculated the Pearson correlation coefficient between tHcy, Cysta
and tCys.We also calculated the Pearson correlation coefficient betweencontinuous variables and tHcy, Cysta and tCys and geometric mean of
the aforementioned metabolites according to categorical variables. We
used Cox regression to obtain hazard ratios (HRs) [95% confidence in-
tervals (CIs)] for incident AF according to quartiles and per one standard
deviation (SD) increase in log-transformed plasma concentrations of
the biomarker of interest. The biomarkers were tested individually
when adjusted for age and gender (Model 1) aswell as in twomultivar-
iatemodels:Model 2 was further adjusted for known risk factors for AF,
including diabetes, hypertension, body mass index (BMI) and smoking.
Model 3 extended Model 2 by further including estimated glomerular
filtration rate (eGFR), anamnestic heart failure, left ventricular ejection
fraction (LVEF), left ventricular end-diastolic pressure (LVEDP), plasma
pyridoxal 5'-phsphate (PLP) and C-reactive protein (CRP). The possibil-
ity for unmeasured confounding was investigated by calculating E-
values to model 3 according to recent recommendations [15].
We explored any non-linear relationships between the biomarkers
and future AF risk by constructing generalized additive model (GAM)
plots.
We investigated reclassification of patients by adding the biomarker
of interest to amultivariate logistic model including age, gender, hyper-
tension, diabetes, BMI and smoking and calculating the continuous net
reclassification improvement (NRI N 0) and the Receiver Operating
Curve Area Under the Curve (ROC-AUC).
All tests were two-sided and the significance level set to 0.05. We
used the software IBM SPSS Statistics for Windows, Version 23.0.
Armonk, NY: IBMCorp., and R forWindows (R Core Team2016, Vienna,
Austria, utilizing the packages #survival, #Hmisc, #PredictABEL, #ROCR,
#ggplot2 and #ICC).
3. Results
3.1. Baseline characteristics in the overall population
At baseline 320 (8.3%) patients had previous or current AF. Median
(25–75 percentiles) plasma tHcy, Cysta and tCys concentrations were
higher among these patients as compared to those without any history
of AF (tHcy 10.9 (8.8–13.4) vs. 10.4 (8.7–12.5) μmol/L; P= 0.005, Cysta
0.30 (0.21–0.47) vs. 0.26 (0.19–0.38) μmol/L; P b 0.0001 and tCys 300
(273–329) vs. 289 (266–313) μmol/L; P b 0.0001). Baseline characteris-
tics according to prevalent AF are shown in Supplemental Table 1. Ac-
cording to Supplemental Fig. 1, tHcy, Cysta and tCys were positively
correlatedwith increasing age andCRP and a negativelywith eGFR. Sup-
plemental Fig. 2 shows that there is very little difference in geometric
mean concentration of all three metabolites in question according to
categorical variables.
The Associations Between Plasma Transsulfuration Metabolites and
Incident Atrial Fibrillation.
During a median (25–75 percentile) follow-up-time of 7.4 (6.2–8.6)
years 392 (10.2%) patients were registered with incident AF. Character-
istics of the patients according to new-onset AF are showed in Table 1.
Patients with incident AF were generally older and were more often
men and having a history of hypertension, diabetes, and heart failure
as compared to those who did not develop AF. The former group also
more often smoked, and had higher CRP and plasma riboflavin, lower
eGFR, as well asmore extensive coronary artery disease at angiography.
Plasma concentrations of tHcy, Cysta and tCys were higher among
those who developed AF compared to those who did not develop AF.
Accordingly, all three metabolites were related to increased risk of AF
during follow-up (Supplemental Table 2 and Figs. 1–3). For tHcy and
tCys these associations were attenuated in model 2 [HRs (95% CI) per
1 log transformed SD 1.23 (1.12–1.35) and 1.23 (1.11–1.38)]; however,
the adjustment rendered Cysta no longer associated with incident AF.
Extensive adjusting in Model 3 yielded similar results [HRs (95% CI)
per 1 log transformed SD 1.20 (1.08–1.34) and 1.20 (1.06–1.36)], as
was the case when including all the three metabolites in the same
model, to check for any mutually attenuating effects (Supplemental
Table 1
Patients characteristics according to new-onset atrial fibrillation.
N New onset atrial fibrillation P
No Yes










tCys, μmol/L 3535 288 (265–311) 302 (278–327) b0.001
Age, years 3535 60 (54–68) 68 (61–74) b0.001
Male gender, % n 3535 71.0 (2220) 75.5 (392) 0.04
Hypertension, % n 3535 44.3 (1392) 57.9 (227) b0.001
Diabetes, % n 3535 11.0 (348) 16.1 (63) 0.004
Smoking, % n 3530 32.5 (1019) 26.3 (103) 0.013
BMI, kg/m2 3535 26.0 (24–28) 26.0 (24–29) 0.962
Anamnestic heart failure 3535 5.6 (177) 11.2 (44) b0.001
Left ventricular ejection
fraction, %
3535 66 (60–70) 65 (58–70) 0.041
Previous AMI, % n 3535 39.7 (1247) 43.4 (170) 0.16
LVEDP, mm Hg 3535 16 (12–20) 18 (12–22) 0.073
Extent of CAD at angiography,
% n
3535 b0.001
No significant stenosis 26.0 (818) 17.3 (68)
1-Vessel disease 23.8 (747) 19.4 (76)
2-Vessel disease 22.2 (698) 23.2 (91)
3-Vessel disease 28.0 (880) 40.0 (157)





C-reactive protein, mg/L 3532 1.7 (0.9–3.5) 2.0 (1.0–3.9) 0.010
Troponin-T, ng/L 3462 4 (3–10) 5 (3–11) 0.220
eGFR, ml/min/1,73m2 3534 92 (80–100) 85 (70–94) b0.001
Lipids, mmol/L
Total cholesterol 3533 5.0 (4.3–5.8) 4.9 (4.2–5.6) 0.201
LDL-cholesterol 3531 3.0 (2.4–3.7) 2.9 (2.4–3.6) 0.397
HDL-cholesterol 3534 1.2 (1.0–1.5) 1.3 (1.0–1.5) 0.243
Alcohol N2 units/week, % n 3535 36.9 (1159) 35.7 (140) 0.077
Physical activity ≥2 days/week,
% n
3535 59.3 (1863) 58,4 (229) 0.70
Plasma and serum B-vitamers










Cobalamin, pmol/L 3153 363 (276–468) 356 (259–465) 0.187





Abbreviations: tHcy: total homocysteine, Cysta: cystathionine, tCys: total cysteine, BMI:
bodymass index, LVEF: left ventricular ejection fraction, AMI: acutemyocardial infarction,
LVEDP: left ventricle end-diastolic pressure, CAD: coronary artery disease, GFR: glomeru-
lar filtration rate LDL: low density lipid, HDL: high density lipid, PLP: pyridoxal phosphate.
Fig. 1. The unadjusted association between total plasma homocysteine and new-onset
atrial fibrillation among patients with suspected stable angina pectoris. The shaded
areas surrounding the solid splines depict 95% confidence intervals.
Fig. 2. The unadjusted association between total plasma cystathionine and new-onset
atrial fibrillation among patients with suspected stable angina pectoris. The shaded
areas surrounding the solid splines depict 95% confidence intervals.
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ity which revealed variance inflation factors between 1.0 and 1.1, thus
ruling out collinearity.We calculated the Pearson correlation coefficient
between the variables which revealed values between 0.23 and 0.45.
Application of the E-value formula to model 3 revealed E-values for
the HR and lower CI of 1.69 and 1.37 for tHcy and 1.69 and 1.31 for tCys.
We found no significant difference in risk estimates between pa-
tients receiving B-vitamin treatment in the WENBIT versus patients
who did not receive B-vitamin supplements (data not shown).
3.2. Reclassification of patients
When adding plasma tHcy or tCys to a logistic regressionmodel con-
taining age, gender, BMI, hypertension, diabetes and smoking, the
NRI N 0 (95% CI) for was 0.118 (0.02–0.22) and 0.107 (0.002–0.21), re-
spectively; however we did not observe any improvement in the ROC-
AUC (Supplementary Table 4).
4. Discussion
The current study showed that plasma tHcy, tCys and Cystawere as-
sociated with previous AF in a population with suspected stable anginapectoris. Plasma tHcy and tCys were also related to increased risk of in-
cident AF, and either metabolite improved the reclassification of pa-
tients beyond traditional risk factors.
4.1. Transsulfuration metabolites and CVD
Previous studies regarding tHcy and transsulfuration metabolites
with CVD have mainly looked into the relationship between themetab-
olites and atherosclerotic cardiovascular events, including acute myo-
cardial infarction and stroke, in addition to all-cause death [3,16–19].
However data regarding transsulfurationmetabolites and AF in particu-
lar is scarce. A positive prospective association between plasma tHcy
and AF is in line with findings from a recent study from a general popu-
lation [7]. However, no association between levels of plasma tHcy and
new-onset AF was found in the Framingham cohort [20]. Discrepancies
Fig. 3. The unadjusted association between total plasma cysteine and new-onset atrial
fibrillation among patients with suspected stable angina pectoris. The shaded areas
surrounding the solid splines depict 95% confidence intervals.
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characteristics, as we studied patient with presumed coronary heart
disease.
4.2. Potential mechanisms
4.2.1. Transsulfuration and methylation
Transsulfuration primarily takes place in hepatocytes; however
some studies suggest that it also can take place in human blood as endo-
thelial cells have been shown to secrete CBS. Hydrogen sulfide (H2S) is
produced during transsulfuration and has been linked to pulmonary
vein and atrial arrhythmogenesis in rats [21,22]. By remethylation,
Hcy is a precursor of S-adenosylmethionine (SAM), which is crucial
for remethylation reactions. Elevated tHcy has been associates with al-
tered DNAmethylation [23], a feature observed in the atrial and pulmo-
nary vein tissue of patients with AF [24], andwhich also has been linked
to increased risk coronary heart disease [25]. In this study thosewhode-
veloped AF were older and more often had hypertension and diabetes,
features which have been linked to altered DNA methylation [26–28].
4.2.2. Electrophysiological Changes
AF is caused by electrical instability in cardiomyocytes in the atria
[29]. Hcy has been shown to affect sodium and potassium ion channels
in human atrial myocytes and may thereby contribute to cardiac excit-
ability and arrhythmogenesis [5,30,31]. tCys has been shown to regulate
cardiac ion channels through its redox state [32], this is further
discussed below.
4.2.3. Inflammation, oxidative stress, atrial cardiomyopathy and fibrosis
AF is associated with inflammation [33]. Elevated tHcy is associated
with up-regulation of NF-kB in mice and increased vascular inflamma-
tion [34], and also known to induce oxidative stress. This may lead to
endothelial dysfunction and reduced NO bioavailability [35], both of
which are associated with AF [36–38].
Moreover, tCys is an antioxidant and takes part in redox reactions
through its reactive thiol groups [39], besides being a precursor of gluta-
thione, an important intracellular antioxidant [2]. The redox state of Cys
is associated with activation of inflammatory gene expression, tissue fi-
brosis and has also been shown to regulate cardiac ion-channels sug-
gesting a possible link to AF [32,40–42]. Notably, recent studies
suggest that AF is the symptom of an underlying atrial cardiomyopathy
[43], and also link AF to atrial fibrosis [44,45]. Mild hyperhomocysteine-
mia is reported to increases collagen formation in rabbit aortic smoothmuscle cells [46], as well as increasing metalloprotease-driven deterio-
ration of elastic fibers [47] and Cys is also shown to contribute to tissue
fibrosis [48]. Hence, the association between tHcy and tCys with AF
could be due to underlying altered atrial morphology and electrophysi-
ological properties related to inflammation and fibrosis, supported by
the finding of increased risk of AF recurrence after radio frequency abla-
tion among patients with elevated tHcy and established AF [8]. The lack
of an association between Cysta and AF, despite the positive relation-
ships between tHcy and tCys with AF, suggests that tHcy and tCys
may be associated with AF through partly independent mechanisms.
In the current study, patients who developed AF had higher serum
CRP, a marker of cardiac fibrosis [49]; however adjusting for CRP as
well as LVEDP as a proxy for elevated left atrial pressure, did also not
alter the risk estimates significantly, suggesting that other mechanisms
are involved in the development of AF.
4.3. Strengths and limitations
The strengths of this study include the large number of patients, the
long-term follow-up and its prospective design. All blood samples were
analyzed by the same core laboratory, reducing the risk of analytical
bias. The biomarkers have shown good reproducibility within subjects
and stability when frozen to −80 °C [50], which favor their use as
biomarkers.
The current study also has limitations. First, although we have made
substantial efforts to control for potential confounders, we cannot rule
out the possibility for residual or unmeasured confounding, as is always
the case for observational studies. However the calculated E-value sug-
gests that such confounding needs to be associated both with tHcy/tCys
and incident AF with a strength of RR N 1.69. We are not aware of any
potential confounder of this strength, conditional on the variables al-
ready included in the fully adjusted model.
Second, the potential for residual confounding is an inherent limita-
tion of observational studies and cannot be ruled out. Second,misclassi-
fication of endpoints may also have occurred when obtaining endpoint
data from health registries. Patients with higher plasma concentrations
of the metabolites of interest also appeared sicker, thus being more
prone to later hospitalization. Third, although tHcy and tCysmoderately
improved reclassification, it is uncertain whether this information can
be utilized in a clinical setting to improve risk stratification. Finally,
the population in this studywas highly selected and consisted primarily
of middle-aged, Caucasian men with established or suspected coronary
heart disease. The risk-associations should therefore be externally con-
firmed in cohorts with other characteristics.
5. Conclusion
This observational cohort study suggests a link betweenmetabolites
in the transsulfuration pathway and incident AF. Our results motivate
further studies in proarrhythmic mechanisms related to one‑carbon
metabolism, and in particular the status of transsulfurationmetabolites.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ijcard.2020.05.010.
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